Due to its unique architecture and innate capability to specifically target cancer cells, ferritin has emerged as an attractive class of biomaterials for drug delivery. In many studies, various chemotherapeutics have been loaded into ferritin nanocages constituted by H-chains of ferritin (HFn), and their related anti-tumor efficacy has been explored by employing different strategies. Despite the multiple advantages and the versatility of HFn-based nanocages, there are still many challenges to face for their reliable implementation as drug nanocarriers in the process of clinical translation. This review aims at providing an overview of the significant efforts expended during recent years to maximize the features of HFn in terms of increased stability and in vivo circulation. The most considerable modification strategies explored to improve bioavailability and pharmacokinetics profiles of HFn-based nanosystems will be discussed herein.

Novel Bioengineering Strategies to Improve Bioavailability and In Vivo Circulation of H-Ferritin Nanocages by Surface Functionalization / M. Sevieri, M. Pinori, A. Chesi, A. Bonizzi, L. Sitia, M. Truffi, C. Morasso, F. Corsi, S. Mazzucchelli. - In: ACS OMEGA. - ISSN 2470-1343. - (2023), pp. 1-8. [10.1021/acsomega.2c07794]

Novel Bioengineering Strategies to Improve Bioavailability and In Vivo Circulation of H-Ferritin Nanocages by Surface Functionalization

M. Sevieri
Primo
;
M. Pinori
Secondo
;
A. Chesi;A. Bonizzi;L. Sitia;M. Truffi;C. Morasso;F. Corsi
Penultimo
;
S. Mazzucchelli
Ultimo
2023

Abstract

Due to its unique architecture and innate capability to specifically target cancer cells, ferritin has emerged as an attractive class of biomaterials for drug delivery. In many studies, various chemotherapeutics have been loaded into ferritin nanocages constituted by H-chains of ferritin (HFn), and their related anti-tumor efficacy has been explored by employing different strategies. Despite the multiple advantages and the versatility of HFn-based nanocages, there are still many challenges to face for their reliable implementation as drug nanocarriers in the process of clinical translation. This review aims at providing an overview of the significant efforts expended during recent years to maximize the features of HFn in terms of increased stability and in vivo circulation. The most considerable modification strategies explored to improve bioavailability and pharmacokinetics profiles of HFn-based nanosystems will be discussed herein.
H-ferritin; Nanoparticles; Modifications; Improved bioavailability;
Settore BIO/10 - Biochimica
Settore BIO/14 - Farmacologia
Settore MED/18 - Chirurgia Generale
2023
17-feb-2023
https://doi.org/10.1021/acsomega.2c07794
Article (author)
File in questo prodotto:
File Dimensione Formato  
acsomega.2c07794.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 4.22 MB
Formato Adobe PDF
4.22 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/956256
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact